Welcome to SuperLan Chemical Co.,Ltd.
Home > Products > Stem Cells & Wnt > Hedgehog/Smoothened > GDC-0449

GDC-0449

(CAS No:879085-55-9)
Vismodegib (GDC-0449) is a potent, novel and specific hedgehog inhibitor with IC50 of 3 nM and also inhibits P-gp with IC50 of 3.0 μM in a cell-free assay.
CAS No:879085-55-9
Molecular Weight(MW):421.3
Purity:99.00%
Specification:500MG;1G;5G;10G;50G;100G
Price and large packaging, please e-mail consultation:info@SuperLan-chem.com
QC Documents
 COA  MSDS  HPLC  NMR
ChemicalInfomation
CAS No: 879085-55-9
Molecular formula(MF) C19H14Cl2N2O3S
Molecular Weight(MW): 421.3
Alias
Solubility
In vitro DMSO 84 mg/mL (199.38 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 10mg/mL
Biological Activity
Description Vismodegib (GDC-0449) is a potent, novel and specific hedgehog inhibitor with IC50 of 3 nM and also inhibits P-gp with IC50 of 3.0 μM in a cell-free assay.
Targets
Hedgehog [1]
(Cell-free assay)
P-gp [1] P-gp [1]
3 nM 3 μM 5 μM
In vitro

GDC-0449 targets the Hedgehog signaling pathway, blocking the activities of the Hedgehog-ligand cell surface receptors PTCH and/or SMO and suppressing Hedgehog signaling. GDC-0449 prevents multiple ATP-binding cassette (ABC) transporters. GDC-0449 also blocks ABCG2, Pgp, and MRP1-important ABC transporters associated with MDR. GDC-0449 is a potent inhibitor of ABC transporters, ABCG2/BCRP and ABCB1/Pgp, and is a mild inhibitor of ABCC1/MRP1. In ABCG2-overexpressing HEK293 cells, GDC-0449 increases retention of the fluorescent ABCG2 substrate BODIPY-prazosin and resensitizes these cells to mitoxantrone. In Madin-Darby canine kidney II cells engineered to overexpress Pgp or MRP1, GDC-0449 increases the retention of calcein-AM and resensitizes them to colchicine. GDC-0449 also resensitizes human non-small cell lung carcinoma cells NCI-H460/par and NCI-H460/MX20, which overexpress ABCG2 in response to mitoxantrone, to mitoxantrone, and to topotecan or SN-38. The IC50 values of GDC-0449 for prevention of ABCG2 and Pgp are about 1.4 μM and 3.0 μM, respectively. [2] GDC-0449 alters intracellular Ca2+ homeostasis and inhibits cell growth in cisplatin-resistant lung cancer cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
IGROV-1 Growth Inhibition Assay IC50=0.07248 μM SANGER
HCE-T Growth Inhibition Assay IC50=1.32247 μM SANGER
D-542MG Growth Inhibition Assay IC50=1.86737 μM SANGER
23132-87 Growth Inhibition Assay IC50=4.40147 μM SANGER
HDLM-2 Growth Inhibition Assay IC50=8.04766 μM SANGER
ACN Growth Inhibition Assay IC50=8.50109 μM SANGER
HuO-3N1 Growth Inhibition Assay IC50=9.60108 μM SANGER
BHT-101 Growth Inhibition Assay IC50=11.38 μM SANGER
KYSE-150 Growth Inhibition Assay IC50=11.5841 μM SANGER
MC-IXC Growth Inhibition Assay IC50=12.2292 μM SANGER
D-423MG Growth Inhibition Assay IC50=12.7657 μM SANGER
NY Growth Inhibition Assay IC50=14.8903 μM SANGER
HOS Growth Inhibition Assay IC50=15.6719 μM SANGER
NB7 Growth Inhibition Assay IC50=15.891 μM SANGER
DMS-273 Growth Inhibition Assay IC50=16.6713 μM SANGER
MDA-MB-361 Growth Inhibition Assay IC50=17.2711 μM SANGER
DU-145 Growth Inhibition Assay IC50=18.32 μM SANGER
NCI-H82 Growth Inhibition Assay IC50=19.8386 μM SANGER
NCI-SNU-1 Growth Inhibition Assay IC50=20.0196 μM SANGER
GCT Growth Inhibition Assay IC50=20.8824 μM SANGER
C2BBe1 Growth Inhibition Assay IC50=21.1058 μM SANGER
LB2241-RCC Growth Inhibition Assay IC50=21.8441 μM SANGER
COLO-829 Growth Inhibition Assay IC50=22.1871 μM SANGER
EW-11 Growth Inhibition Assay IC50=22.8022 μM SANGER
NCI-H526 Growth Inhibition Assay IC50=23.4717 μM SANGER
SF295 Growth Inhibition Assay IC50=24.0252 μM SANGER
D-566MG Growth Inhibition Assay IC50=25.2943 μM SANGER
8505C Growth Inhibition Assay IC50=25.6331 μM SANGER
HT-29 Growth Inhibition Assay IC50=26.0431 μM SANGER
NBsusSR Growth Inhibition Assay IC50=26.8006 μM SANGER
BV-173 Growth Inhibition Assay IC50=28.3182 μM SANGER
CTB-1 Growth Inhibition Assay IC50=30.1031 μM SANGER
JAR Growth Inhibition Assay IC50=32.5371 μM SANGER
CAMA-1 Growth Inhibition Assay IC50=33.4615 μM SANGER
CAL-51 Growth Inhibition Assay IC50=34.7176 μM SANGER
A172 Growth Inhibition Assay IC50=37.4921 μM SANGER
QIMR-WIL Growth Inhibition Assay IC50=38.0708 μM SANGER
AsPC-1 Growth Inhibition Assay IC50=38.4651 μM SANGER
MKN7 Growth Inhibition Assay IC50=39.0079 μM SANGER
ONS-76 Growth Inhibition Assay IC50=43.3057 μM SANGER
RS4-11 Growth Inhibition Assay IC50=44.0752 μM SANGER
NOS-1 Growth Inhibition Assay IC50=44.6031 μM SANGER
A101D Growth Inhibition Assay IC50=44.8023 μM SANGER
HCC1806 Growth Inhibition Assay IC50=46.1148 μM SANGER
CAL-27 Growth Inhibition Assay IC50=47.7246 μM SANGER
BT-549 Growth Inhibition Assay IC50=48.5315 μM SANGER
LCLC-97TM1 Growth Inhibition Assay IC50=49.2413 μM SANGER
A4-Fuk Growth Inhibition Assay IC50=49.849 μM SANGER
OVCAR-4 Growth Inhibition Assay IC50=50.0601 μM SANGER
HD-MY-Z Growth Inhibition Assay IC50=50.7764 μM SANGER
NCI-H292 Growth Inhibition Assay IC50=50.8758 μM SANGER
Sk-ChA-1  Growth Inhibition Assay 0.25–50 μM 72 h IC50=74.54±2.58μM 25742482
Mz-ChA-1 Growth Inhibition Assay 0.25–50 μM 72 h IC50=54.97±3.45μM 25742482
Smo-WT Growth Inhibition Assay IC50 of 14 nM 24291104
Smo-D473H  Growth Inhibition Assay IC50 of 7.1 μM 24291104
K562 Function Assay 10 μM 72 h reduces the expression of Gli1  23319824
T315I BCR-ABL BaF3 Function Assay 10 μM 72 h reduces the expression of Gli1  23319824
TF-1 BCR-ABL Function Assay 10 μM 72 h reduces the expression of Gli1  23319824

... Click to View More Cell Line Experimental Data

In vivo GDC-0449 has been used to treat medulloblastoma in animal models. [2] GDC-0449 prevents the growth of primary pancreatic xenografts without non-specifically inhibiting pancreatic cell proliferation. Oral dosing of GDC-0449 causes tumor regressions in the Ptch(+/-) allograft model of medulloblastoma at doses ≥25 mg/kg and tumor growth inhibition at doses up to 92 mg/kg dosed twice daily in two ligand-dependent colorectal cancer models, D5123, and 1040830. Analysis of Hh pathway activity and PK/PD modeling reveals that GDC-0449 inhibits Gli1 with a similar IC50 in both the medulloblastoma and D5123 models (0.165 μM and 0.267 μM, respectively). Pathway modulation is linked to efficacy using an integrated PK/PD model revealing a steep relationship where > 50% of the activity of GDC-0449 is associated with >80% repression of the Hh pathway. [4]